Look at this way... From a share price perspective, as long as it gets approved, it doesn't so much matter whether it's on time, or whether it's early, the current share price is an insane discount either way, as the market seems intent on punishing the stock because it hasn't already received early approval, which is ridiculous.
In fact, after the big day, shorts started crowing "nice results, but if it doesn't get early approval, $45 is not justified."
Phooey! I say.
Before those results came, were longs in this stock for early approval?
Longs were in it for results. And we got great results in the amount of boys tested. I contend the whole early approval hoopla was more or less promoted by shorts as a way to attack the stock.
The current share price should be $45 imo based on results. Early approval or not.
From a parent and patient perspective, hopefully the good people at the FDA get this approved ASAP.
There better be NO PROTECTIONISM of any competitors. And surely any delay could be viewed by some people as accessory to something.... You can fill in your own something.